Table 2.
Effect of dose and treatment duration among current users as compared with non use.
| Cases (n = 65) | Controls (n = 247) | Adjusted* odds ratio (95% CI) | ||
|---|---|---|---|---|
| Duration of treatment (number of prescriptions) | ||||
| SSRIs | 1–2 | 4 | 8 | 1.6 (0.4,5.6) |
| 3 | 3 | 16 | 0.6 (0.2,2.2) | |
| Others | 1–2 | 6 | 19 | 1.1 (0.4,3.0) |
| 3 | 5 | 32 | 0.6 (0.2,1.5) | |
| Daily doses | ||||
| SSRIs | Low-medium† | 4 | 12 | 1.1 (0.3,3.8) |
| High | 3 | 12 | 0.6 (0.1,3.0) | |
| Others | Low-medium‡ | 10 | 39 | 0.9 (0.4,2.0) |
| High | 1 | 12 | 0.3 (0.0,2.4) | |
*
Adjusted for age, sex, calendar time and practice (the adjustment for hypertension, smoking, body mass index, asthma/COPD, migraine and NSAID use did not change the estimates).
†
Fluoxetine: ≤ 20 mg; fluvoxamine: ≤ 100 mg: paroxetine: ≤ 20 mg; sertraline: ≤ 50 mg; citalopram: ≤ 20 mg; clomipramine: ≤ 75 mg; trazodone: ≤ 125 mg
‡
Amitriptyline: ≤ 75 mg; dothiepin: ≤ 75 mg; imipramine: ≤ 75 mg; doxepin: ≤ 75 mg; lofepramine: ≤ 140 mg.